Ganglioside-antibodies produced subsequent to Campylobacter jejuni infection may play a role in the pathogenesis of the neurological disorder Guillain-Barré syndrome (GBS). Since lipopolysaccharides (LPS) of certain C. jejuni serotypes associated with GBS (O:2, O:4, O:19) exhibit structural mimicry of gangliosides in their core oligosaccharides, we investigated antibody and ligand cross-reactivities between gangliosides and LPS of these C. jejuni serotypes. GM1-antibody reacted with O:19 LPS reflecting GM1 mimicry by the O:19 core oligosaccharide. On the other hand, asialoGM1-antibody bound to O:2 and O:19 LPS indicating a shared epitope not dependent on ganglioside mimicry. Serum IgA from GBS patients after C. jejuni infection reacted with gangliosides, predominantly GM1, and LPS of all three serotypes. Cholera toxin (GM1 ligand) recognized O:4 and O:19 LPS, whereas peanut agglutinin (Galβ1-3GalNAc ligand) recognized LPS of all three serotypes, thereby confirming structural mimicry. These results suggest that LPS from certain C. jejuni strains may function as cross-reactive antigens for anti-ganglioside B cells.
Get full access to this article
View all access options for this article.
References
1.
Ropper AHCampylobacter diarrhea and Guillain-Barré syndrome. Arch Neurol1988; 45: 655-656.
2.
Winer JB, Hughes Rac, Anderson MJ, Jones DM, Kangro H., Watkins Rpf.A prospective study of acute idiopathic neuropathy. II. Antecedent events . J Neurol Neurosurg Psychiatry1988; 51: 613-618.
3.
Kaldor J., Speed BRGuillain-Barré syndrome and Campylobacter jejeuni: a serological study. BMJ1984; 288: 1867-1870.
Kuroki S., Saida T., Nukina M. et al. Campylobacter jejuni strains from patients with Guillain-Barré syndrome belong mostly to Penner serogroup 19 and contain β-N-acetylglucosamine residues. Ann Neurol1993; 33: 243-247.
6.
Penner JL, Hennessy JN, Congi RVSerotyping of Campylobacter jejuni and Campylobacter coli on the basis of thermostable antigens. Eur J Clin Microbiol1983; 2: 378-383.
7.
Mishu B., Ho TW, Li CY et al. Guillain-Barré syndrome (GBS), acute motor axonal neuropathy and C. jejuni infection. Acta Gastroenterol Belg1993; 56 (Suppl.): 9.
8.
Yuki N., Sato S., Fujimoto S. et al. Serotype of Campylobacter jejuni. HLA, and the Guillain-Barré syndrome (letter). Muscle Nerve1992; 15: 968-969.
9.
Jacobs BC, Oomes PG, Hazenberg MP, Bänffer JR J, van Doom PA, van der Meché FGA. Epitopes on Campylobacter jejuni/coli can be recognized by anti-GM1 IgG antibodies in sera of Guillain-Barré patients . Acta Gastroenterol Belg1993; 56 (Suppl.): 9.
10.
Obayashi H. , Saida T., Kuroki S., Nukina M., Nishitani Y.Guillain-Barré syndrome and Campylobacter jejuni infection. Shinkei Naika1993; 38: 431-438.
11.
Griffin JW, Ho Twh.The Guillain-Barré syndrome at 75: the Campylobacter connection. Ann Neurol1993; 34: 125-127.
Van der Meché Fga, Schmitz Pim, and the Dutch Guillain-Barré Study Group.A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med1992; 326: 1123-1129.
16.
Fredman P., Vedeler CA, Nyland H., Aarli JA, Svennerholm L.Antibodies in sera from patients with inflammatory demyelinating polyradiculoneuropathy react with ganglioside LM and sulphatide of peripheral nerve myelin. J Neurol1991; 238: 75-79.
17.
Ilyas AA, Mithen FA, Chen ZW, Cook SDSearch for antibodies to neutral glycolipids in sera of patients with Guillain-Barré syndrome. J Neurol Sci1991; 102: 67-75.
18.
Ilyas AA, Mithen FA, Chen ZW, Cook SDAnti-GM1 IgA antibodies in Guillain-Barré syndrome. J Neuroimmunol1992; 36: 69-76.
19.
Ilyas AA, Mithen FA, Dalakas MC, Chen ZW, Cook SDAntibodies to acidic glycolipids in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. J Neurol Sci1992; 107: 111-121.
20.
Weller M., Stevens A., Sommer N., Dichgans J., Kappler B., Wiethölter H.Ganglioside antibodies: a lack of diagnostic specificity and clinical utility?J Neurol1992; 239: 455-459.
21.
Chiba A., Kusunoki S., Obata H., Machinami R., Kanazawa I.Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies. Neurology1993; 43: 1911-1917.
22.
Yuki N., Yamada M., Sato S. et al. Association of IgG anti-GD1a antibody with severe Guillain-Barré syndrome. Muscle Nerve1993; 16:642-647.
23.
Yuki N., Yoshino H., Sato S., Miyatake T.Acute axonal polyneuropathy associated with anti-GM1 antibodies following Campylobacter enteritis. Neurology1990; 40: 1900-1902.
24.
Yuki N., Sato S., Itoh T., Miyatake T.HLA-B35 and acute axonal polyneuropathy following Campylobacter infection . Neurology1991; 41: 1561-1563.
25.
Walsh FS, Cronin M., Koblar S. et al. Association between glycoconjugate antibodies and Campylobacter infection in patients with Guillain-Barré syndrome. J Neuroimmunol1991; 34: 43-51.
26.
Nobile-Orazio E., Carpo M., Meucci N. et al. Guillain-Barré syndrome associated with high titers of anti-GM1 antibodies. J Neurol Sci1991; 109: 200-206.
27.
Gregson NA, Koblar S., Hughes Rac.Antibodies to gangliosides in Guillain-Barré syndrome: specificity and relationship to clinical features. Q J Med1993; 86: 111-117.
28.
Kusunoki S. , Chiba A., Kon K. et al. N-acetyl-galactosaminyl GD1a is a target molecule for serum antibody in Guillain-Barré syndrome. Ann Neurol1994; 35: 570-576.
29.
Rees JH, Hughes Rac.Campylobacter jejuni and Guillain-Barré syndrome. Ann Neurol1994; 35: 248-249.
30.
Sugita K., Ishii M., Takanashi J., Niimi H., Yuki N.Guillain-Barré syndrome associated with IgM anti-GM1 antibody following Campylobacter jejuni enteritis. Eur J Pediatr1994; 153: 181-183.
31.
von Wulffen H., Hartard C., Scharein E.Seroreactivity to Campylobacter jejuni and gangliosides in patients with Guillain-Barré syndrome. J Infect Dis1994; 170: 828-833.
32.
Enders U., Karch H., Toyka KV et al. The spectrum of immune responses to Campylobacter jejuni and glycoconjugates in Guillain-Barré syndrome and in other neuroimmunological disorders. Ann Neurol1993; 34: 136-144.
33.
Vriesendorp FJ, Mishu B., Blaser MJ, Koski CLSerum antibodies to GM1, GD1b, peripheral nerve myelin, and Campylobacter jejuni in patients with Guillain-Barré syndrome and controls: correlation and prognosis. Ann Neurol1993 ; 34: 130-135.
34.
Van den Berg LH, Marrink J., de Jager Aej et al. Anti-GM1 antibodies in patients with Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry1992; 55: 8-11.
35.
Seiser A., Pötzl G., Safoschnik G., Pichler S., Bemheimer H., Schwerer B.GM1 antibodies in Guillain-Barré syndrome: isotypes, course and clinical outcome . Wien Klin Wochenschr1994; 106: 159-163.
36.
Moran AP, Rietschel ET, Kosunen TU, Zähringer U.Chemical characterization of Campylobacter jejuni lipopolysaccharides containing N-acetylneuraminic acid and 2,3-diamino-2,3-dideoxy-D-glucose. J Bacteriol1991; 173: 618-626.
37.
Aspinall GO , McDonald AG, Raju TS, Pang H., Moran AP, Penner JLChemical structures of the core regions of Campylobacter jejuni serotypes O:1, O:4, O:23, and O:36 lipopolysaccharides . Eur J Biochem1993; 213: 1017-1027.
38.
Aspinall GO , McDonald AG, Raju TS et al. Chemical structure of the core region of Campylobacter jejuni serotype O:2 lipopolysaccharide. Eur J Biochem1993; 213: 1029-1037.
39.
Yuki N., Taki T., Inagaki F. et al. A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure. J Exp Med1993; 178: 1771-1775.
40.
Aspinall GO, McDonald AG, Pang H., Kurjanczyk LA, Penner JLLipopolysaccharides of Campylobacterjejuni serotype O:19: structures of core oligosaccharide regions from the serostrain and two bacterial isolates from patients with the Guillain-Barré syndrome. Biochemistry1994; 33: 241-249.
41.
Aspinall GO, Fujimoto S., McDonald AG, Pang H., Kurjanczyk LAPenner JLLipopolysaccharides from Campylobacter jejuni associated with Guillain-Barré syndrome patients mimic human gangliosides in structure. Infect Immun1994; 62: 2122-2125.
42.
Moran AP, Kosunen TUSerological analysis of the heat stable antigens involved in serotyping Campylobactet jejuni and Campylobacter coli. APMIS1989; 97: 253-260.
43.
Saito M., Kasai N.Yu RKIn situ immunological determination of basic carbohydrate structures of gangliosides on thin-layer plates. Anal Biochem1985; 148: 54-58.
44.
Yuki N. Handa S., Taki T. et al. Cross-reactive antigen between nervous tissue and a bacterium elicits Guillain-Barré syndrome: molecular mimicry between ganglioside GM1 and lipopolysaccharide from Penner's serotype 19 of Campylobacter jejuni. Biomed Res1992; 13: 451-453.
45.
Schwimmer S. , Bevenue A.Reagent for differentiation of 1,4- and 1,6-linked glucosaccharides. Science1956 ; 123: 543-544.
46.
Mishu B., Blaser MJRole of infection due to Campylobacter jejuni in the initiation of Guillain-Barré syndrome. Clin Infect Dis1993. 17: 104-108.
47.
The Guillain-Barré Syndrome Study Group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology1985 ; 35: 1096-1104.
48.
Latov N. Koski CL, Walicke PAGuillain-Barré syndrome and parenteral gangliosides . Lancet1991; 338: 757.
49.
Figueras A. , Morales-Olivas FJ, Capella D., Palop V., Laporte JRBovine gangliosides and acute motor polyneuropathy . BMJ1992; 305: 1330-1331.
50.
Yuki N., Taki T., Takahashi M. et al. Penner's serotype 4 of Campylobacter jejuni has a lipopolysaccharide that bears a GM1 ganglioside epitope as well as one that bears a GD1a epitope . Infect Immun1994; 62: 2101-2103.
51.
Preston MA, Penner JLStructural and antigenic properties of lipopolysaccharides from serotype reference strains of Campylobacterjejuni. Infect Immun1987; 55: 1806-1812.
52.
Preston MA, Penner JLCharacterization of cross-reacting serotypes of Campylobacter jejuni. Can J Microbiol1989; 35: 265-273.
53.
Wirguin I., Suturkova-Milosevic L., Della-Latta P., Fisher T., Brown R.H., Latov N.Monoclonal IgM antibodies to GM1 and asialo-GM1 in chronic neuropathies cross-react with Campylobacter jejuni lipopolysaccharides. Ann Neurol1994; 35: 698-703.
54.
Sadiq SA, Thomas FP, Kilidireas K. et al. The spectrum of neurological disease associated with anti-GM1 antibodies. Neurology1990; 40: 1067-1072.
55.
Lee KW, Inghirami G., Sadiq SA et al. B-cells that express anti-MAG or anti-GM1 antibodies are present at birth and anti-MAG antibody B cells are CD5+. Neurology1991; 40 (suppl 1): 367.
56.
Daikoku T., Kawaguchi M., Takama K., Suzuki S.Partial purification and characterization of the enterotoxin produced by Campylobacterjejuni . Infect Immun1990; 58: 2414-2419.
